Portal Vein Thrombosis disease: Malacards - Research Articles, Drugs, Genes, Clinical Trials

MCID: PRT018 MIFTS: 52	Portal Vein Thrombosis Categories: Blood diseases, Cardiovascular diseases, Gastrointestinal diseases, Liver diseases	Data Licensing For inquiries, contact: [email protected]
Genes Tissues Related diseases Publications Drugs Expand all tables

Sources

Aliases & Classifications for Portal Vein Thrombosis

MalaCards integrated aliases for Portal Vein Thrombosis:

Name: Portal Vein Thrombosis ¹¹ ⁷⁵ ²⁸ ⁵³ ¹⁴ ⁷¹ ³¹ ³³

Deep Vein Thrombosis of Portal Vein ³³

Occlusion of Hepatic Portal Vein ³³

Hepatic Portal Vein Obstruction ³³

Pvt - [portal Vein Thrombosis] ³³

Portal Venous Obstruction ³³

Phlebitis of Portal Vein ³³

Portal Venous Thrombosis ³³

Portal Vein Obstruction ³³

Portal Venous Embolism ³³

Portal Vein Embolism ³³

Portal Venous Block ³³

Portal Obstruction ³³

Portal Thrombosis ³³

Portal Vein Block ³³

Portal Embolism ³³

Portal Block ³³

Classifications:

MalaCards categories:
Anatomical: Cardiovascular diseases Gastrointestinal diseases Liver diseases Blood diseases

See all MalaCards categories (disease lists)

ICD10: ³¹

Diseases of the circulatory system

Diseases of veins, lymphatic vessels and lymph nodes, not elsewhere classified

Portal vein thrombosis

ICD11: ³³

Diseases of the digestive system

Diseases of liver

Vascular disorders of the liver

Portal vein thrombosis

External Ids:

Disease Ontology ¹¹ DOID:11695

ICD9CM ³⁴ 452

NCIt ⁴⁹ C78565

SNOMED-CT ⁶⁸ 155455003

ICD10 ³¹ I81

ICD11 ³³ 866276949

UMLS ⁷¹ C0155773

Sources

Summaries for Portal Vein Thrombosis

Disease Ontology: ¹¹ A hepatic vascular disease that is characterized by a blood clot that forms within the hepatic portal vein.

MalaCards based summary: Portal Vein Thrombosis, also known as deep vein thrombosis of portal vein, is related to hepatic encephalopathy and liver cirrhosis. An important gene associated with Portal Vein Thrombosis is F2 (Coagulation Factor II, Thrombin), and among its related pathways/superpathways are Response to elevated platelet cytosolic Ca2+ and Collagen chain trimerization. The drugs Heparin, bovine and Ethiodized oil have been mentioned in the context of this disorder. Affiliated tissues include liver, neutrophil and endothelial, and related phenotypes are homeostasis/metabolism and cardiovascular system

Wikipedia: ⁷⁵ Portal vein thrombosis (PVT) is a vascular disease of the liver that occurs when a blood clot occurs in... more...

Sources

Related Diseases for Portal Vein Thrombosis

Diseases related to Portal Vein Thrombosis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 809)

#	Related Disease	Score	Top Affiliating Genes
1	hepatic encephalopathy	31.5	GPT F2 ALB
2	liver cirrhosis	31.5	THPO SERPINC1 GPT F3 F2 ALB
3	portal hypertension	31.4	THPO PIGM JAK2 GPT F2 ALB
4	varicose veins	31.3	VWF THBD SERPINC1 MTHFR F5 F2
5	vitamin k deficiency bleeding	31.1	SERPINC1 F8 F3 F2 AFP
6	alcoholic liver cirrhosis	31.0	GPT F2 ALB AFP
7	biliary atresia	31.0	GPT F2 ALB
8	non-alcoholic steatohepatitis	31.0	GPT ALB AFP
9	liver disease	31.0	THPO GPT F3 F2 ALB AFP
10	cholecystitis	30.9	GPT F2 CRP ALB
11	homocysteinemia	30.9	MTHFR F5 F2
12	hemophilia	30.8	VWF F8 F2
13	cavernous hemangioma	30.8	VWF SERPINC1 F3 F2 ALB AFP
14	autoimmune hepatitis	30.8	GPT F2 CD40LG ALB
15	hepatitis b	30.7	GPT F2 ALB AFP
16	cholangitis	30.7	GPT F3 F2 CRP ALB
17	protein c deficiency	30.7	THBD SERPINC1 MTHFR F5 F2 APOH
18	factor vii deficiency	30.7	SERPINC1 F8 F3 F2
19	hypersplenism	30.7	THPO SERPINC1 GPT F3 F2 ALB
20	hepatorenal syndrome	30.6	GPT F2 ALB AFP
21	factor viii deficiency	30.6	VWF SERPINC1 F8 F5 F3 F2
22	klatskin's tumor	30.6	GPT F2 ALB AFP
23	esophageal varix	30.6	THPO SERPINC1 GPT F3 F2 CRP
24	protein s deficiency	30.5	THBD SERPINC1 MTHFR F5 F3 F2
25	obstructive jaundice	30.5	GPT F2 CRP ALB AFP
26	acute kidney failure	30.5	GPT F2 ALB
27	primary biliary cholangitis	30.4	GPT F2 CD40LG ALB AFP
28	pregnancy loss, recurrent 1	30.4	MTHFR F5 APOH
29	choledocholithiasis	30.4	GPT F2 CRP ALB
30	covid-19	30.4	PLG F3 F2 CRP
31	acute vascular insufficiency of intestine	30.4	SERPINC1 CRP ALB
32	wilson disease	30.4	GPT F2 ALB
33	schistosomiasis	30.4	GPT F2 CRP CD40LG ALB
34	hepatic tuberculosis	30.4	GPT F2 ALB AFP
35	hemophilia a	30.4	VWF F8 F5 F3 F2
36	lymph node tuberculosis	30.3	CRP ALB
37	polyarteritis nodosa	30.3	GPT CRP APOH
38	alcohol use disorder	30.3	GPT F2 CRP ALB AFP
39	severe acute respiratory syndrome	30.3	GPT F3 CRP
40	thrombocythemia 1	30.3	THPO MPL
41	protein-losing enteropathy	30.3	SERPINC1 GPT F2 CRP ALB
42	abdominal tuberculosis	30.2	GPT F2 CRP ALB AFP
43	cholelithiasis	30.2	GPT CRP ALB
44	heparin-induced thrombocytopenia	30.2	PF4 F3 F2
45	diarrhea	30.2	VWF GPT CD40LG ALB
46	bowel dysfunction	30.2	GPT CRP ALB
47	dengue disease	30.2	GPT CD40LG ALB
48	hepatic infarction	30.2	SERPINC1 GPT F3 F2 APOH ALB
49	nephrotic syndrome	30.2	SERPINC1 PLG F3 F2 CRP ALB
50	sclerosing cholangitis	30.1	GPT F2 CRP ALB AFP

Comorbidity relations with Portal Vein Thrombosis via Phenotypic Disease Network (PDN):

Active Peptic Ulcer Disease	Acute Vascular Insufficiency of Intestine
Hepatic Encephalopathy	Portal Hypertension

Graphical network of the top 20 diseases related to Portal Vein Thrombosis:

Sources

Symptoms & Phenotypes for Portal Vein Thrombosis

GenomeRNAi Phenotypes related to Portal Vein Thrombosis according to GeneCards Suite gene sharing:

²⁵

#	Description	GenomeRNAi Source Accession	Score	Top Affiliating Genes
1	no effect	GR00402-S-1	10.18	AFP ALB APOH CD40LG CRP F2
2	no effect	GR00402-S-2	10.18	ALB APOH CD40LG CRP F2 F3

MGI Mouse Phenotypes related to Portal Vein Thrombosis:

⁴⁵

#	Description	MGI Source Accession	Score	Top Affiliating Genes
1	homeostasis/metabolism	MP:0005376	10.28	AFP ALB APOH CD40LG CRP F2
2	cardiovascular system	MP:0005385	10	ALB CD40LG CRP F2 F3 F5
3	liver/biliary system	MP:0005370	9.97	AFP ALB F5 JAK2 MTHFR PLG
4	immune system	MP:0005387	9.97	ALB CD40LG CRP F2 F3 F8
5	hematopoietic system	MP:0005397	9.73	CD40LG F2 F3 F8 JAK2 MPL
6	mortality/aging	MP:0010768	9.5	ALB APOH CD40LG F2 F3 F5

Sources

Drugs & Therapeutics for Portal Vein Thrombosis

Drugs for Portal Vein Thrombosis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 91)

Name

Status

Phase

Clinical Trials

Cas Number

PubChem Id

Heparin, bovine

Approved, Investigational, Withdrawn

Phase 4

9005-49-6

22833565 9812414 772

Ethiodized oil

Approved, Investigational

Phase 4

8008-53-5

Cisplatin

Approved

Phase 4

15663-27-1

2767 5702198 441203

Warfarin

Approved

Phase 4

81-81-2, 129-06-6

54678486

Benzocaine

Approved, Investigational

Phase 4

1994-09-7, 94-09-7

2337

Tannic acid

Approved

Phase 4

1401-55-4

16129878 16129778

Nadroparin

Approved, Investigational

Phase 4

Apixaban

Approved

Phase 4

503612-47-3

10182969

Reviparin

Approved, Investigational

Phase 4

9041-08-1

Acetylsalicylic acid

Approved, Vet_approved

Phase 4

50-78-2

2244

Dipyridamole

Approved

Phase 4

58-32-2

3108

Fibrinolytic Agents

Phase 4

Anticoagulants

Phase 4

Calcium heparin

Phase 4

Pharmaceutical Solutions

Phase 4

Gelatin Sponge, Absorbable

Phase 4

Calcium, Dietary

Phase 4

Factor Xa Inhibitors

Phase 4

HIV Protease Inhibitors

Phase 4

Serine Proteinase Inhibitors

Phase 4

Antithrombins

Phase 4

Antithrombin III

Phase 4

Heparin, Low-Molecular-Weight

Phase 4

protease inhibitors

Phase 4

Liver Extracts

Phase 4

Vasodilator Agents

Phase 4

Analgesics

Phase 4

Antirheumatic Agents

Phase 4

Antipyretics

Phase 4

Phosphodiesterase Inhibitors

Phase 4

Cyclooxygenase Inhibitors

Phase 4

Platelet Aggregation Inhibitors

Phase 4

Anti-Inflammatory Agents, Non-Steroidal

Phase 4

Analgesics, Non-Narcotic

Phase 4

Anti-Inflammatory Agents

Phase 4

Calcium

Nutraceutical

Phase 4

7440-70-2

271

Serine

Investigational, Nutraceutical

Phase 4

56-45-1

5951

Rivaroxaban

Approved

Phase 3

366789-02-8

9875401

Propranolol

Approved, Investigational

Phase 3

318-98-9, 525-66-6

62882 4946

Simvastatin

Approved

Phase 3

79902-63-9

54454

Sorafenib

Approved, Investigational

Phase 3

284461-73-0

216239

Neurotransmitter Agents

Phase 3

Adrenergic Antagonists

Phase 3

Adrenergic Agents

Phase 3

Antihypertensive Agents

Phase 3

Anti-Arrhythmia Agents

Phase 3

Antimetabolites

Phase 3

Hypolipidemic Agents

Phase 3

Anticholesteremic Agents

Phase 3

Hydroxymethylglutaryl-CoA Reductase Inhibitors

Phase 3

Interventional clinical trials:

(show top 50) (show all 61)

#	Name	Status	NCT ID	Phase	Drugs
1	Effect of Anticoagulation After Endoscopic Therapy in Cirrhotic Patients With Portal Vein Thrombosis：A Zelen-design Multicenter Randomized Controlled Trial	Unknown status	NCT02630095	Phase 4	Nadroparin Calcium and Warfarin
2	A Zelen-design Randomized Controlled Trial of the Effect of Anticoagulation After Endoscopic Therapy in Cirrhotic Patients With Portal Vein Thrombosis	Unknown status	NCT02398357	Phase 4	Nadroparin Calcium and Warfarin
3	Efficacy and Safety of Warfarin Anticoagulation for Prevention of Portal Vein Thrombosis in Liver Cirrhotic Patients With Hypersplenism After Laparoscopic Splenectomy	Unknown status	NCT02238444	Phase 4	Warfarin;Dipyridamole;Aspirin;Low Molecular Weight Heparin
4	Efficacy and Safety of Nadroparin Calcium-Warfarin Sequential Anticoagulation in Portal Vein Thrombosis in Cirrhotic Patients：A Randomized Controlled Trial	Completed	NCT04173429	Phase 4	Nadroparin calcium, warfarin
5	Initiation of NWS Anticoagulation Therapy After Oesophageal Variceal Band Ligation Was Safe in Portal Vein Thrombosis Patients With Cirrhosis and Acute Variceal Bleeding: A Multi-central Randomized Controlled Trial	Completed	NCT04976543	Phase 4	nadroparin calcium-warfarin sequential anticoagulation
6	Efficacy and Safety of Warfarin Anticoagulation for Prevention of Portal Vein Thrombosis in Liver Cirrhotic Patients After Laparoscopic Splenectomy and Azygoportal Disconnection for Portal Hypertension	Completed	NCT02247414	Phase 4	Warfarin;Dipyridamole;Aspirin;Low Molecular Weight Heparin
7	Outcome of Transarterial Chemo-embolization (TACE) in Hepatocellular Carcinoma Patients With Partial Portal Vein Thrombosis	Completed	NCT03007212	Phase 4
8	Efficacy and Safety of Apixaban, Warfarin and Aspirin Anticoagulation for Prevention of Portal Vein Thrombosis in Liver Cirrhotic Patients After Laparoscopic Splenectomy	Recruiting	NCT04645550	Phase 4	Apixaban;Warfarin;Aspirin;Dipyridamole;Low molecular weight heparin
9	Treatment of Portal, Mesenteric, and Splenic Vein Thrombosis With Rivaroxaban. A Pilot, Prospective Cohort Study	Unknown status	NCT02627053	Phase 3	rivaroxaban
10	Efficacy and Safety of Rivaroxaban in the Management of Acute Non-neoplastic Portal Vein Thrombosis in HCV Related Compensated Cirrhosis	Unknown status	NCT03193502	Phase 3	rivaroxaban
11	Transjugular Intrahepatic Portosystemic Shunt (TIPS) for Variceal Rebleeding in Cirrhotic Patients With Occlusive Portal Vein Thrombosis (PVT) and Cavernous Transformation of the Portal Vein (CTPV)	Unknown status	NCT02853526	Phase 3	Propranolol;Warfarin
12	Minimal Hepatic Encephalopathy in Pre-hepatic Portal Hypertension Due to Portal Vein Thrombosis in Childhood and Young Adult: epidemiOlogical Study and Pilot Interventional Study.	Unknown status	NCT01798329	Phase 3
13	A Phase III, Randomized, Open Label Study Evaluating the Safety of Apixaban in Subjects With Cancer Related Venous Thromboembolism	Completed	NCT02585713	Phase 3	Apixaban;Dalteparin
14	Placebo-controlled Study of NPB-06 in Patients With Portal Vein Thrombosis	Completed	NCT02250391	Phase 3	NPB-06;Placebo
15	Multicentric Randomized Study of Xarelto Versus no Treatment for the Prevention of Recurrent Thrombosis in Patients With Chronic Portal Vein Thrombosis.	Completed	NCT02555111	Phase 3	Xarelto
16	A Randomized, Multicenter,Double Blind,Controlled With Placebo Trial About Efficacy of Statin Association With Standard Treatment in Prevention of Recurrent Hemorrhage in Patient With Liver Cirrhosis and Variceal Bleeding	Completed	NCT01095185	Phase 3	Simvastatin;Placebo
17	SBRT Sequential TACE Combined With Sorafenib Versus Sorafenib Alone in the Treatment of Unresectable Hepatocellular Carcinoma With Portal Vein Tumor Thrombus：A Single-center Randomized Controlled Study	Recruiting	NCT04387695	Phase 3	Sorafenib
18	A Prospective Randomized Clinical Trial on 90Yttrium Trans-arterial Radio-Embolization (TheraSphere®) vs. Standard of Care (Sorafenib) for the Treatment of Advanced Hepatocellular Carcinoma (HCC) With Portal Vein Thrombosis (PVT)	Terminated	NCT01887717	Phase 3	Sorafenib
19	An Investigator-initiated, Multicentre, Randomized, Trial Comparing Anticoagulation Alone Versus Transjugular Intrahepatic Portosystemic Shunt (TIPS) and Anticoagulation in Patients With Recent Obstructive Portal Vein Thrombosis	Withdrawn	NCT03422419	Phase 3	Heparin
20	Randomized Trial of Sorafenib Plus Hepatic Arterial Infusion With Oxaliplatin and Fluorouracil Versus Sorafenib for Hepatocellular Carcinoma With Major Portal Vein Tumor Thrombosis	Completed	NCT03009461	Phase 2	Sorafenib
21	Proton Beam Radiotherapy Followed by Tecentriq and Avastin for Primary Liver Cancer With Vp2-4 Portal Vein Invasion: PORTAL Study	Recruiting	NCT05625893	Phase 2
22	Hepatic Arterial Infusion Chemotherapy Combine With Lenvatinib and Camrelizumab for Advanced Hepatocellular Carcinoma With Portal Vein Tumor Thrombosis.	Recruiting	NCT05166239	Phase 2	Lenvatinib 1;Camrelizumab 1;Lenvatinib 2;Camrelizumab 2
23	A Randomized, Double-blinded, Controlled Phase II Study of Combination Therapy of HAIC (Hepatic Arterial Infusion Chemotherapy), HLX10 (PD-1 Antibody) and HLX04 (VEGF Antibody) Compared With HAIC and Placebo in Hepatocellular Carcinoma With Major Portal Vein Tumor Thrombosis	Not yet recruiting	NCT04947826	Phase 2	HLX10 (PD-1 antibody);HLX04 (VEGF antibody);Placebo
24	Phase Ib/II Trial of Combining Pembrolizumab and Lenvatinib With Stereotactic Body Radiotherapy for Hepatocellular Carcinoma Patients With Portal Vein Thrombosis.	Not yet recruiting	NCT05286320	Phase 1, Phase 2	Lenvatinib/Pembrolizumab plus SBRT combinations
25	Effect of Anticoagulation in Reducing the Incidence of Splenic/Portal Vein Thrombosis Post-Laparoscopic Splenectomy Protocol Number: 5698	Terminated	NCT00769873	Phase 2	Enoxaparin
26	Preventing de Novo Portal Vein Thrombosis With Antithrombin-III in Patients With Cirrhosis: A Randomized, Double-blinded, Placebo - Controlled Trial (PiVoT-AC Trial)	Withdrawn	NCT04055389	Phase 1	Antithrombin III
27	Role of Endoscopic Ultrasound Guided Fine Needle Aspiration of Portal Vein Thrombus in the Diagnosis and Staging of Hepatocellular Carcinoma	Unknown status	NCT03902678
28	Comparison in Portal Flow After Sleeve Gastrectomy and Mini Gastric Bypass	Unknown status	NCT02733770
29	The Effect of Rifaximin on Portal Vein Thrombosis in Cirrhotic Patients	Unknown status	NCT03631147		Rifaximin
30	Radiotherapy in Hepatocellular Carcinomas After Hepatectomy With Narrow Margin (<1 cm) or Portal Vein Thrombosis	Unknown status	NCT02309788
31	STUDY OF THE ADAMTS-13 LEVEL AS PREDICTIVE BIOMARKER FOR DEVELOPMENT OF PORTAL VEIN THROMBOSIS IN LIVER CIRRHOSIS	Unknown status	NCT03322696
32	Incidence of Venous Thromboembolic Disease and Portal Vein Thrombosis After Hepatectomy in a High-volume Center. A Cohort Study.	Unknown status	NCT02597218
33	A Practical Nomogram Based on Systemic Inflammatory Markers for Predicting Portal Vein Thrombosis in Patients With Liver Cirrhosis	Completed	NCT05541562
34	Prevalence and Predictive Factors of Portal Vein Thrombosis in Patients With Cirrhosis	Completed	NCT02069457
35	Outcomes of Surgical Strategies for Living Donor Liver Transplantation to Patients With Portal Vein Thrombosis	Completed	NCT05132192
36	Efficacy and Safety of Rivaroxaban in the Management of Acute Non-neoplastic Portal Vein Thrombosis in HCV Related Compensated Cirrhosis	Completed	NCT03201367		Rivaroxaban
37	EASYX-1 : A Multicenter Study on Safety and Efficacy of Easyx Liquid Embolization Agent Used in Five Separate Indications	Completed	NCT03477149
38	Analysis of Neutrophil Extracellular Traps in Hypercoagulability and Portal Vein Thrombosis in Liver Cirrhosis Patients	Completed	NCT05012501
39	Risk Factors for Recurrence of Thrombosis or Thrombotic Extension, in the Event of Acute Non-cirrhotic Portal Vein Thrombosis Secondary to a Local Cause.	Completed	NCT05360641
40	A Humanitarian Device Exemption Treatment Protocol of TheraSphere for Treatment of Unresectable Hepatocellular Carcinoma in Patients With Portal Vein Thrombosis	Completed	NCT01556282
41	Portal Vein Thrombosis Relevance On Liver Cirrhosis: Italian Venous Thrombotic Events Registry	Completed	NCT01470547
42	Transjugular Intrahepatic Portosystemic Shunt Versus Endoscopic Treatment Combined With Propranolol for Prevention of Variceal Rebleeding in Cirrhotic Patients With Portal Vein Thrombosis: A Randomized Controlled Trial	Completed	NCT01326949
43	Screening for Asymptomatic Portal Vein Thrombosis and Portal Hypertension in Patients With Philadelphia Negative Myeloproliferative Neoplasms	Completed	NCT01816256
44	Proteomic Analysis of Human Hepatocellular Carcinoma Associated With Portal Vein Thrombosis	Completed	NCT01177631
45	Pair Production PET Imaging to Detect Particle Distribution in Patients Undergoing Yttrium-90 Radioembolization With Large Hepatocellular Carcinomas or Associated Portal Vein Thrombosis	Completed	NCT02848638
46	Neoadjuvant Transartery Chemoembolization Plus Artery Infusion Chemotherapy With Surgery Versus Surgery Alone for Hepatocellular Carcinoma Patients With Portal Vein Tumor Thrombus: a Randomized Clinical Trial	Recruiting	NCT04181931
47	Follow-up and Survival of Cirrhotic and Non Cirrhotic Patients With Portal Vein Thrombosis Treated With Transjugular Intrahepatic Portosystemic Shunt	Recruiting	NCT03031717
48	Vienna Vascular Liver Disease Study: Characterization of Patients With Vascular Liver Disease - a Registry With Biobank	Recruiting	NCT03541057
49	Prospective Evaluation of Coagulation Status and Thromboelastometry Guided Management of Genetic and Acquired Thrombophilia in Patients With Portal Vein Thrombosis and Budd-Chiari Syndrome	Recruiting	NCT05123326
50	Efficacy and Safety of Dabigatran in Patients With Cirrhosis and Portal Vein Thrombosis-A Randomized Placebo Controlled Trial	Recruiting	NCT04433481		Dabigatran

Search NIH Clinical Center for Portal Vein Thrombosis

Sources

Genetic Tests for Portal Vein Thrombosis

Genetic tests related to Portal Vein Thrombosis:

#	Genetic test	Affiliating Genes
1	Portal Vein Thrombosis ²⁸

Sources

Anatomical Context for Portal Vein Thrombosis

Organs/tissues related to Portal Vein Thrombosis:

MalaCards : Liver, Neutrophil, Endothelial, Spleen, Myeloid, Pancreatic Islet, Pancreas

Sources

Publications for Portal Vein Thrombosis

Articles related to Portal Vein Thrombosis:

(show top 50) (show all 5788)

#	Title	Authors	PMID	Year
1	Portal vein thrombosis treated using danaparoid sodium and antithrombin III. ⁵³ ⁶²	Uchiyama T...Nakajima A	20422871	2010
2	Impact of antithrombin III concentrates on portal vein thrombosis after splenectomy in patients with liver cirrhosis and hypersplenism. ⁵³ ⁶²	Kawanaka H...Maehara Y	19864937	2010
3	Tumor and liver determinants of prognosis in unresectable hepatocellular carcinoma: a large case cohort study. ⁵³ ⁶²	Carr BI...Branch RA	20305756	2009
4	Resolution of preoperative portal vein thrombosis after administration of antithrombin III in living donor liver transplantation: case report. ⁵³ ⁶²	Imai H...Uemoto S	19917415	2009
5	Combination of sorafenib and intensity modulated radiotherapy for unresectable hepatocellular carcinoma. ⁵³ ⁶²	Hsieh CH...Chen YJ	19067476	2009
6	Is the Cancer of the Liver Italian Program system an adequate weighting for survival of hepatocellular carcinoma? Evaluation of intrascore prognostic value among 36 subgroups. ⁵³ ⁶²	Lin CY...Lu SN	18331238	2009
7	Prognostic factors of survival in patients with non-resectable hepatocellular carcinoma: hepatitis C versus miscellaneous etiology. ⁵³ ⁶²	Abbas Z...Rizvi AH	19024130	2008
8	Tumor and liver determinants of prognosis in unresectable hepatocellular carcinoma: a case cohort study. ⁵³ ⁶²	Carr BI...Branch RA	18699979	2008
9	Predictive factors of tumor response to trans-catheter treatment in cirrhotic patients with hepatocellular carcinoma: a multivariate analysis of pre-treatment findings. ⁵³ ⁶²	Miraglia R...Gridelli B	18023093	2007
10	High FVIII level is associated with idiopathic portal vein thrombosis in South India. ⁵³ ⁶²	Koshy A...Jeyakumari M	17524760	2007
11	A simple prognostic scoring system for patients with unresectable hepatocellular carcinoma treated by chemo-embolization. ⁵³ ⁶²	Dvorchik I...Carr BI	17416468	2007
12	Idiopathic portal vein thrombosis and FVIII levels. ⁵³ ⁶²	Akar N	17011614	2007
13	Factor V Leiden and prothrombin gene G20210A mutations are uncommon in portal vein thrombosis in India. ⁵³ ⁶²	Sharma S...Aggarwal R	17090840	2006
14	[Modified CLIP score as a new prognostic index for patients with hepatocellular carcinoma]. ⁵³ ⁶²	Han SH...Lee SW	16804346	2006
15	Combination of repeated single-session percutaneous ethanol injection and transarterial chemoembolisation compared to repeated single-session percutaneous ethanol injection in patients with non-resectable hepatocellular carcinoma. ⁵³ ⁶²	Dettmer A...Bleck JS	16773687	2006
16	Factor V Leiden is not commonly associated with idiopathic portal vein thrombosis in southern India. ⁵³ ⁶²	Koshy A...Jeyakumari M	16877827	2006
17	[Survival analysis for patients with hepatocellular carcinoma according to stage, liver function and treatment modalities]. ⁵³ ⁶²	Park KW...Kim CM	16565605	2006
18	Increased plasma prothrombin concentration in cirrhotic patients with portal vein thrombosis and prothrombin G20210A mutation. ⁵³ ⁶²	Amitrano L...Balzano A	16493481	2006
19	Mesenteric and portal vein thrombosis associated with hyperhomocysteinemia and heterozygosity for factor V Leiden mutation. ⁵³ ⁶²	Famularo G...Simone CD	16437705	2005
20	Causes of portal venous thrombosis in cirrhotic patients: the role of genetic and acquired factors. ⁵³ ⁶²	Mangia A...Andriulli A	15947552	2005
21	Prognostic factors for survival in patients with early-intermediate hepatocellular carcinoma undergoing non-surgical therapy: comparison of Okuda, CLIP, and BCLC staging systems in a single Italian centre. ⁵³ ⁶²	Grieco A...Gasbarrini G	15710992	2005
22	Prevalence of factor V Leiden mutation and other hereditary thrombophilic factors in Egyptian children with portal vein thrombosis: results of a single-center case-control study. ⁵³ ⁶²	El-Karaksy H...A-Kader H	15309526	2004
23	Three-dimensional conformal radiation therapy for unresectable hepatocellular carcinoma patients who had failed with or were unsuited for transcatheter arterial chemoembolization. ⁵³ ⁶²	Liu MT...Lin JP	15466827	2004
24	Preliminary analysis of a newly proposed prognostic scoring system (SLiDe score) for hepatocellular carcinoma. ⁵³ ⁶²	Omagari K...Kohno S	15209629	2004
25	Portal vein thrombosis complicating islet transplantation in a recipient with the Factor V Leiden mutation. ⁵³ ⁶²	Brennan DC...Shapiro J	15257060	2004
26	Inherited prothrombotic defects in Budd-Chiari syndrome and portal vein thrombosis: a study from North India. ⁵³ ⁶²	Bhattacharyya M...Saxena R	15198356	2004
27	Pathologic analysis of right-lobe graft failure in adult-to-adult live donor liver transplantation. ⁵³ ⁶²	Pantanowitz L...Khettry U	14615823	2003
28	[Portal vein thrombosis associated with factor V Leiden mutation in a woman who underwent exchange transfusion at birth]. ⁵³ ⁶²	Tchuenbou J...Metman EH	12910230	2003
29	[Thrombophilic disorders in children and adolescents with portal vein thrombosis]. ⁵³ ⁶²	Pinto RB...Bandinelli E	14502338	2003
30	Detection of circulating hepatocellular carcinoma cells in peripheral venous blood by reverse transcription-polymerase chain reaction. ⁵³ ⁶²	Liu Y...Zhang BH	14607627	2002
31	Plasma thrombopoietin in patients with cavernous transformation of the portal vein. ⁵³ ⁶²	Goker H...Bayraktar Y	11843299	2002
32	[Relation between transcatheter arterial chemoembolization and time of death in patients with hepatic carcinoma]. ⁵³ ⁶²	Cheng H...Chen D	11859720	2001
33	Hereditary thrombophilia as a cause of Budd-Chiari syndrome: a study from Western India. ⁵³ ⁶²	Mohanty D...Abraham P	11584361	2001
34	Hepatocellular carcinoma in Central Europe: prognostic features and survival. ⁵³ ⁶²	Schoniger-Hekele M...Gangl A	11115830	2001
35	Clinical characteristics and prognosis of hepatocellular carcinoma: analysis based on serum alpha-fetoprotein levels. ⁵³ ⁶²	Tangkijvanich P...Poovorawan Y	11129271	2000
36	Abdominal venous thrombosis in neonates and infants: role of prothrombotic risk factors - a multicentre case-control study. For the Childhood Thrombophilia Study Group. ⁵³ ⁶²	Heller C...Nowak-Gottl U	11122096	2000
37	Factor V Leiden mutation, prothrombin gene mutation, and deficiencies in coagulation inhibitors associated with Budd-Chiari syndrome and portal vein thrombosis: results of a case-control study. ⁵³ ⁶²	Janssen HL...Rosendaal FR	11001884	2000
38	Prospective validation of the CLIP score: a new prognostic system for patients with cirrhosis and hepatocellular carcinoma. The Cancer of the Liver Italian Program (CLIP) Investigators. ⁵³ ⁶²		10733537	2000
39	Deficiency of natural anticoagulant proteins C, S, and antithrombin in portal vein thrombosis: a secondary phenomenon? ⁵³ ⁶²	Fisher NC...Elias E	10716684	2000
40	The role of natural anticoagulant deficiencies and factor V Leiden in the development of idiopathic portal vein thrombosis. ⁵³ ⁶²	Egesel T...Bayraktar Y	10636214	2000
41	Paraneoplastic syndromes in patients with hepatocellular carcinoma in Taiwan. ⁵³ ⁶²	Luo JC...Lee SD	10463978	1999
42	[Resistance to activated protein C and portal vein thrombosis: two new cases and review of the literature]. ⁵³ ⁶²	Cretel E...Piette JC	10434351	1999
43	Frequent factor II G20210A mutation in idiopathic portal vein thrombosis. ⁵³ ⁶²	Chamouard P...Oudet P	9869612	1999
44	Survival benefit of patients with inoperable hepatocellular carcinoma treated by a combination of transarterial chemoembolization and percutaneous ethanol injection--a single-center analysis including 132 patients. ⁵³ ⁶²	Allgaier HP...Blum HE	9842968	1998
45	[The detection of circulating hepatocellular carcinoma cells in peripheral venous blood by reverse transcription-polymerase chain reaction and its clinical significance]. ⁵³ ⁶²	Liu Y...Huang C	11825477	1998
46	A new prognostic system for hepatocellular carcinoma: a retrospective study of 435 patients: the Cancer of the Liver Italian Program (CLIP) investigators. ⁵³ ⁶²		9731568	1998
47	[Successful treatment of hepatocellular carcinoma with All-trans-retinoic acid]. ⁵³ ⁶²	Egyed M...Horvath G	9569727	1998
48	Portal vein thrombosis in association with factor V Leiden mutation in a patient with hepatocellular carcinoma. ⁵³ ⁶²	Gurgey A...Gogus S	9212850	1997
49	Prevalence of the factor V Leiden mutation in hepatic and portal vein thrombosis. ⁵³ ⁶²	Mahmoud AE...Wilde JT	9245936	1997
50	Factor V Leiden is not common in children with portal vein thrombosis. ⁵³ ⁶²	Seixas CA...Annichino-Bizzacchi JM	9157577	1997

Sources

Genes for Portal Vein Thrombosis

Genes related to Portal Vein Thrombosis (0 elite genes):

(show all 21)

- Elite gene

- Cancer Census gene in COSMIC

#	Symbol	Description	Category	Score	Evidence	PubMed IDs
1	F2	Coagulation Factor II, Thrombin	Protein Coding	24.59	DISEASES inferred ¹⁴ Novoseek inferred ⁵³ GeneCards inferred via : Publications (show sections)	11115830 11122096 16493481 (more) 18023093
2	SERPINC1	Serpin Family C Member 1	Protein Coding	24.05	DISEASES inferred ¹⁴ Novoseek inferred ⁵³ GeneCards inferred via : Publications (show sections)	14502338 7486227 19864937 (more) 15198356 19917415 11001884 11584361 1603050 10716684 20422871
3	F5	Coagulation Factor V	Protein Coding	22.21	DISEASES inferred ¹⁴ Novoseek inferred ⁵³ GeneCards inferred via : Publications (show sections)	16877827 10434351 8522125 (more) 10636214 11001884 9245936 14502338 14615823 15309526 16437705 12910230 11584361 17090840 15257060 11122096 9157577 9869612 9212850 15947552
4	PIGM	Phosphatidylinositol Glycan Anchor Biosynthesis Class M	Protein Coding	21.89	DISEASES inferred ¹⁴ GeneCards inferred via : Disorders Publications (show sections)
5	AFP	Alpha Fetoprotein	Protein Coding	17.54	DISEASES inferred ¹⁴ Novoseek inferred ⁵³	9842968 9731568 11115830 (more) 18331238 10733537 19024130 10463978 16773687 15710992 20305756 18023093 11859720 19067476 17416468 16804346 18699979 15466827 14607627 11825477 11129271 15209629 16565605 9569727
6	MTHFR	Methylenetetrahydrofolate Reductase	Protein Coding	14.98	DISEASES inferred ¹⁴ GeneCards inferred via : Publications (show sections)
7	APOH	Apolipoprotein H	Protein Coding	12.71	DISEASES inferred ¹⁴ GeneCards inferred via : Publications (show sections)
8	CD40LG	CD40 Ligand	Protein Coding	10.67	DISEASES inferred ¹⁴ GeneCards inferred via : Publications (show sections)
9	F8	Coagulation Factor VIII	Protein Coding	8.35	DISEASES inferred ¹⁴ Novoseek inferred ⁵³	17524760 17011614
10	THPO	Thrombopoietin	Protein Coding	8.31	DISEASES inferred ¹⁴ Novoseek inferred ⁵³	11843299
11	ALB	Albumin	Protein Coding	7.74	DISEASES inferred ¹⁴
12	GPT	Glutamic--Pyruvic Transaminase	Protein Coding	7.32	DISEASES inferred ¹⁴
13	F3	Coagulation Factor III, Tissue Factor	Protein Coding	7.02	DISEASES inferred ¹⁴
14	JAK2	Janus Kinase 2	Protein Coding	6.79	DISEASES inferred ¹⁴
15	VWF	Von Willebrand Factor	Protein Coding	6.44	DISEASES inferred ¹⁴
16	PLG	Plasminogen	Protein Coding	6.2	DISEASES inferred ¹⁴
17	CRP	C-Reactive Protein	Protein Coding	6.16	DISEASES inferred ¹⁴
18	THBD	Thrombomodulin	Protein Coding	6.12	DISEASES inferred ¹⁴
19	PF4	Platelet Factor 4	Protein Coding	6.12	DISEASES inferred ¹⁴
20	MPL	MPL Proto-Oncogene, Thrombopoietin Receptor	Protein Coding	6.1	DISEASES inferred ¹⁴
21	F7	Coagulation Factor VII	Protein Coding	5.9	DISEASES inferred ¹⁴

Sources

Variations for Portal Vein Thrombosis

Sources

Expression for Portal Vein Thrombosis

Search GEO for disease gene expression data for Portal Vein Thrombosis.

Sources

Pathways for Portal Vein Thrombosis

Pathways related to Portal Vein Thrombosis according to GeneCards Suite gene sharing:

#	Super pathways	Score	Top Affiliating Genes
1	Response to elevated platelet cytosolic Ca2+ ⁶⁶ Show member pathways Disinhibition of SNARE formation ⁶⁶ Hemostasis ⁶⁶ Platelet activation, signaling and aggregation ⁶⁶ Platelet degranulation ⁶⁶	12.53	VWF THPO THBD SERPINC1 PLG PF4
2	Collagen chain trimerization ⁶⁶ Show member pathways Anchoring fibril formation ⁶⁶ Assembly of collagen fibrils and other multimeric structures ⁶⁶ Blood Coagulation Cascade ⁶⁴ Collagen biosynthesis and modifying enzymes ⁶⁶ Collagen degradation ⁶⁶ Collagen formation ⁶⁶ Crosslinking of collagen fibrils ⁶⁶ Intrinsic Prothrombin Activation Pathway ⁶⁴	12.5	THBD SERPINC1 F8 F5 F3 F2
3	Defects of contact activation system (CAS) and kallikrein/kinin system (KKS) ⁶⁶ Show member pathways Blood clotting cascade ⁷⁴ Blood Coagulation Signaling Pathways ⁶⁵ Common Pathway of Fibrin Clot Formation ⁶⁶ Complement and coagulation cascades ⁷⁴ Defective F8 binding to von Willebrand factor ⁶⁶ Defective F8 cleavage by thrombin ⁶⁶ Defective F8 sulfation at Y1699 ⁶⁶ Defective F9 activation ⁶⁶ Defective F9 secretion ⁶⁶ Defective factor IX causes hemophilia B ⁶⁶ Defective factor VIII causes hemophilia A ⁶⁶ Defective factor XII causes hereditary angioedema ⁶⁶ Defective gamma-carboxylation of F9 ⁶⁶ Diseases of hemostasis ⁶⁶ Extrinsic Pathway of Fibrin Clot Formation ⁶⁶ Extrinsic Prothrombin Activation Pathway ⁶⁴ Formation of Fibrin Clot (Clotting Cascade) ⁶⁶ Intrinsic Pathway of Fibrin Clot Formation ⁶⁶ Thrombin/protease-activated receptor (PAR) pathway ⁶¹	12.07	VWF THBD SERPINC1 PLG PF4 F8
4	Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs) ⁶⁶ Show member pathways Post-translational protein phosphorylation ⁶⁶	12	AFP ALB F2 F5 PLG SERPINC1
5	Visual Cycle in Retinal Rods ⁶⁴	11.64	THPO MPL JAK2 CRP
6	Integrin signaling ⁶⁶ Show member pathways GRB2:SOS provides linkage to MAPK signaling for Integrins ⁶⁶ p130Cas linkage to MAPK signaling for integrins ⁶⁶ Platelet Aggregation (Plug Formation) ⁶⁶	11.54	VWF THPO MPL F2
7	FOXA2 and FOXA3 transcription factor networks ⁶¹ Show member pathways FOXA transcription factor networks ⁶¹	11.24	F2 ALB AFP
8	Heparin-induced Thrombocytopenia Pathway, Adverse Drug Reaction ⁶⁰	11.15	PF4 F3 F2
9	COVID-19, thrombosis and anticoagulation ⁷⁴	10.3	PLG F2

Sources

GO Terms for Portal Vein Thrombosis

Cellular components related to Portal Vein Thrombosis according to GeneCards Suite gene sharing:

#	Name	GO ID	Score	Top Affiliating Genes
1	extracellular region	GO:0005576	10.25	AFP ALB APOH CD40LG CRP F2
2	endoplasmic reticulum lumen	GO:0005788	10.1	SERPINC1 F8 F5 F2 ALB AFP
3	collagen-containing extracellular matrix	GO:0062023	10.1	APOH F2 F3 PF4 PLG SERPINC1
4	blood microparticle	GO:0072562	9.97	SERPINC1 PLG F2 ALB
5	extracellular space	GO:0005615	9.81	AFP ALB APOH CD40LG CRP F2
6	platelet alpha granule lumen	GO:0031093	9.73	VWF PLG PF4 F8 F5 ALB

Biological processes related to Portal Vein Thrombosis according to GeneCards Suite gene sharing:

#	Name	GO ID	Score	Top Affiliating Genes
1	platelet activation	GO:0030168	9.97	VWF PF4 F2 CD40LG
2	acute-phase response	GO:0006953	9.88	F8 F2 CRP
3	blood coagulation	GO:0007596	9.86	VWF THBD SERPINC1 PLG F8 F5
4	negative regulation of fibrinolysis	GO:0051918	9.76	APOH F2 PLG THBD
5	thrombopoietin-mediated signaling pathway	GO:0038163	9.73	THPO MPL
6	regulation of blood coagulation	GO:0030193	9.62	SERPINC1 F2 APOH
7	regulation of body fluid levels	GO:0050878	9.43	F8 F5 F2
8	hemostasis	GO:0007599	9.28	VWF THBD SERPINC1 PLG F8 F5